MX9306006A - Combinaciones antagonistas ibuprofeno-h2. - Google Patents
Combinaciones antagonistas ibuprofeno-h2.Info
- Publication number
- MX9306006A MX9306006A MX9306006A MX9306006A MX9306006A MX 9306006 A MX9306006 A MX 9306006A MX 9306006 A MX9306006 A MX 9306006A MX 9306006 A MX9306006 A MX 9306006A MX 9306006 A MX9306006 A MX 9306006A
- Authority
- MX
- Mexico
- Prior art keywords
- ibuprofen
- heartburn
- lysine
- relief
- salt
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 201000006549 dyspepsia Diseases 0.000 abstract 4
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 208000024798 heartburn Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 210000002784 stomach Anatomy 0.000 abstract 2
- IHHXIUAEPKVVII-PYTFSAHDSA-N (2r)-2,6-diaminohexanoic acid;(2s)-2-[4-(2-methylpropyl)phenyl]propanoic acid Chemical compound NCCCC[C@@H](N)C(O)=O.CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 IHHXIUAEPKVVII-PYTFSAHDSA-N 0.000 abstract 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 abstract 1
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- IHHXIUAEPKVVII-PTKYJSHISA-N [(5s)-5-amino-5-carboxypentyl]azanium;(2s)-2-[4-(2-methylpropyl)phenyl]propanoate Chemical group NCCCC[C@H](N)C(O)=O.CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 IHHXIUAEPKVVII-PTKYJSHISA-N 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 abstract 1
- 229960001680 ibuprofen Drugs 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020830 overeating Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95344092A | 1992-09-29 | 1992-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9306006A true MX9306006A (es) | 1995-01-31 |
Family
ID=25493996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9306006A MX9306006A (es) | 1992-09-29 | 1993-09-28 | Combinaciones antagonistas ibuprofeno-h2. |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0663839A4 (fr) |
| JP (1) | JPH08502254A (fr) |
| AU (1) | AU4931693A (fr) |
| CA (1) | CA2144155A1 (fr) |
| MX (1) | MX9306006A (fr) |
| WO (1) | WO1994007541A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1140066A4 (fr) | 1998-11-17 | 2005-11-09 | Nitromed Inc | Composes et compositions antagonistes de recepteurs de h 2? nitroses et nitrosyles et procedes d'utilisation |
| SE0000774D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| MXPA03011017A (es) | 2001-06-01 | 2005-04-29 | Pozen Inc | Composiciones farmaceuticas para la entrega coordinada de nsaids. |
| SE0102993D0 (sv) | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
| CN101257800B (zh) * | 2005-07-18 | 2012-07-18 | 好利用医疗公司 | 包含法莫替丁和布洛芬的药物 |
| US20080020040A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Unit dose form for administration of ibuprofen |
| US8067451B2 (en) | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
| US8067033B2 (en) | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
| CA2657928C (fr) * | 2006-07-18 | 2014-12-02 | Horizon Therapeutics, Inc. | Procedes et medicaments destines a l'administration d'ibuprofene |
| CA2930063C (fr) | 2008-01-04 | 2017-01-31 | Schabar Research Associates Llc | Compositions de dose orale unitaire solide de naproxene sodique et de nizatidine |
| CA2736547C (fr) | 2008-09-09 | 2016-11-01 | Pozen Inc. | Procede d'administration d'une composition pharmaceutique a un patient en ayant besoin |
| JP2012531409A (ja) | 2009-06-25 | 2012-12-10 | アストラゼネカ・アクチエボラーグ | Ｎｓａｉｄ関連潰瘍を発症するリスクがある患者の処置方法 |
| EP2797600A4 (fr) | 2011-12-28 | 2015-09-16 | Pozen Inc | Compositions et procédés d'administration d'oméprazole plus acide acétylsalicylique améliorés |
| WO2015163832A1 (fr) * | 2014-04-25 | 2015-10-29 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Composition combinée d'ibuprofène et de famotidine ayant une stabilité améliorée |
| US11324727B2 (en) | 2020-07-15 | 2022-05-10 | Schabar Research Associates, Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
| IL299845A (en) | 2020-07-15 | 2023-03-01 | Schabar Res Associates Llc | Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2105193B (en) * | 1981-09-04 | 1984-09-12 | Glaxo Group Ltd | Pharmaceutical compositions containing non-steroidal anti-inflammatory agents |
| NZ235877A (en) * | 1989-11-02 | 1992-09-25 | Mcneil Ppc Inc | Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence |
| US4994604A (en) * | 1990-01-10 | 1991-02-19 | Merck & Co., Inc. | Formation and resolution of ibuprofen lysinate |
| US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
-
1993
- 1993-09-21 JP JP6509138A patent/JPH08502254A/ja active Pending
- 1993-09-21 CA CA002144155A patent/CA2144155A1/fr not_active Abandoned
- 1993-09-21 AU AU49316/93A patent/AU4931693A/en not_active Abandoned
- 1993-09-21 EP EP93921709A patent/EP0663839A4/fr not_active Withdrawn
- 1993-09-21 WO PCT/US1993/008947 patent/WO1994007541A1/fr not_active Ceased
- 1993-09-28 MX MX9306006A patent/MX9306006A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0663839A1 (fr) | 1995-07-26 |
| WO1994007541A1 (fr) | 1994-04-14 |
| AU4931693A (en) | 1994-04-26 |
| JPH08502254A (ja) | 1996-03-12 |
| EP0663839A4 (fr) | 1998-06-03 |
| CA2144155A1 (fr) | 1994-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9306006A (es) | Combinaciones antagonistas ibuprofeno-h2. | |
| Ferrer-Brechner et al. | Combination therapy with ibuprofen and methadone for chronic cancer pain | |
| US4704405A (en) | Rapid acting combination of sodium sulindac and a base | |
| US6689399B1 (en) | Transdermal delivery of an anti-inflammatory composition | |
| EP0320551A1 (fr) | Compositions NSAID protégées contre les lésions gastro-intestinales avec un mélange de certains bloqueurs de récepteurs H1 et H2 | |
| AU582182B2 (en) | Antidiarryheal compositions and use thereof | |
| NZ235877A (en) | Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence | |
| MXPA03000712A (es) | Composiciones farmaceuticas para el tratamiento de condiciones ulcerativas, dolorosas e inflamatorias de superficies epiteliales humedas tales como mucositis, estomatitis y sindorme de behcet. | |
| JPH04230330A (ja) | 非ステロイド系抗炎症薬によつて起こる胃腸症候の緩和のための薬剤配合物と緩和法 | |
| MX9304564A (es) | Combinaciones de relajante muscular-ibuprofen. | |
| FR2385398A1 (fr) | Compositions anti-inflammatoires contenant un compose du type phosphonate et un compose du type salicylate | |
| AU656140B2 (en) | Pharmaceutical compositions and methods for alleviating gastrointestinal distress symptoms induced by nonsteroidal anti-inflammatory drugs | |
| MX9304563A (es) | Combinaciones de dexibuprofen/antiacido/simeticona | |
| DE3366910D1 (en) | Pharmaceutical compositions and preparation thereof | |
| Mardirossian et al. | Comparison of the analgesic efficacy of flurbiprofen and aspirin for postsurgical dental pain | |
| JPH0314812B2 (fr) | ||
| Stalnikowicz et al. | Cimetidine decreases indomethacin induced duodenal mucosal damage in patients with acute musculoskeletal disorders. | |
| EP0017169B1 (fr) | Combinaisons anti-inflammatoires avec un effet ulcérogène réduit | |
| WHEATLEY | Analgesic properties of fluproquazone | |
| IL70407A (en) | Synergistic analgesic pharmaceutical compositions in unit dosage form,comprising an analgesic agent and hydroxyzine | |
| Rodrigo et al. | Sucralfate and cimetidine as maintenance treatment in the prevention of duodenal ulcer recurrence | |
| Paladini et al. | Prophylactic and therapeutic role of rioprostil in NSAIDs induced gastroduodenal lesions | |
| Bakshi et al. | Efficacy and tolerability of diclofenac dispersible in painful osteoarthrosis | |
| Babb | Cimetidine: clinical uses and possible side effects | |
| Tams | Newer Concepts in Gastrointestinal Therapeutics in Small Animals |